



AlzPred-SVV: Free Web Tool for Alzheimer Prediction using Spectroscopy Voxel Volume

Virginia Mato Abad ^{1,*}, Cristian R. Munteanu ², Carlos Fernández-Lozano ² and Alejandro Pazos ²

¹ Rey Juan Carlos University, Móstoles, Spain; E-Mail: virginia.mato@urjc.es

² RNASA-IMEDIR Group, Faculty of Computer Science, University of A Coruna, Spain; E-Mails: crm.publish@gmail.com (C.M.), carlos.fernandez@udc.es (C.F.); apazos@udc.es (A.P.)

* E-Mail: virginia.mato@urjc.es; Tel.: +34 914888522.

Published: 4 December 2015

Abstract: Neuroimaging data from magnetic resonance techniques are widely used as non-invasive biomarkers for the evaluation and early diagnosis of Alzheimer's Disease (AD). Alzheimer Prediction by Spectroscopy Voxel Volume is a free Web tool to predict the AD diagnosis (AlzPred-SVV: <http://bio-aims.udc.es/AlzPredSVV.php>). The inputs are two variables related to a voxel acquired in the left hippocampus: The total volume and the volume of CSF contained in the voxel. The classification method is based on Machine Learning techniques. The tool is based on an HTML/PHP user interface with a Python/Java implementation of the model.

Keywords: Magnetic Resonance Spectroscopy; Alzheimer's Disease; Machine-learning; Single-Layer Perceptron;

1. Introduction


Several magnetic resonance techniques have been proposed as non-invasive imaging biomarkers for the evaluation of disease progression and early diagnosis of AD [1] and mild cognitive impairment (MCI), a transitional state between healthy ageing and AD [2]. The analysis of these biomarkers allows the study of differences between groups but they are not applicable on a single-subject level and do not improve the clinical diagnosis potential. Machine-learning

techniques have been identified as promising tools in neuroimaging data for individual class prediction [3]. Magnetic resonance spectroscopy (¹H-MRS) is a useful technique in the study of the AD [4-5]. We found that just the volumes of grey and white matter (GM,WM) and cerebrospinal fluid (CSF) within the spectroscopic voxel provide a high correlation with the diagnosed groups showing a strong potential for classify healthy controls, MCI and AD subjects [6].

2. Results and Discussion

Alzheimer Prediction by Spectroscopy Voxel Volume (AlzPred-SVV) is a free Web tool (bio-aims.udc.es/AlzPredSVV.php) to predict the AD diagnosis, based on only 2 variables related to the spectroscopic voxel in the left hippocampus: The total voxel volume and volume of CSF contained in the voxel (Figure 1). This tool is on the free portal Bio-AIMS [7] that offers models based on Artificial Intelligence, Computational Biology and Bioinformatics. The website provides the values of predicted class and error

prediction achieved by the model. Inputs should be written using the format `<Label Total_vol CSF_vol>` up to a maximum of 10 rows. Figure 1 shows an example for 4 inputs, labelled as Case1 to Case4 varying the voxel volumes and the CSF proportions. Results are displayed in Figure 2, showing the prediction for each case: 3 inputs are classified as AD with different error predictions and the other one as healthy control.



Ibero-NBIC Network
RNASA-IMEDIR, TIC
Computer Science Faculty
University of A Coruña
Spain

AlzPredSVV @ Bio-AIMS
Modelling the reality

Home | Links | About

AlzPred-SVV
Alzheimer Prediction by Spectroscopy Voxel Volume

Model: Multilayer Perceptron
Software: Weka (for model prediction)
Features: Two values from spectroscopy voxel acquired in the left hippocampus: total voxel volume and volume of cerebrospinal fluid contained in the voxel
True Positive Rate = 0.812 | **False Positive Rate** = 0.204

Please paste your data using space-delimited columns
AnyLabel+Space+Total voxel volume+Space+Cerebrospinal fluid volume (maximum 10 rows)

```
Case1 3.5 2.4  
Case2 4.3 4.2  
Case3 4.5 1.0  
Case4 2.0 0.9
```

Predict

Figure 1. AlzPred-SVV website

```
Process ID = 21679563b3bbcbbedb  
... please wait ....  
Calculating ...  
Result file = Results/21679563b3bbcbbedb/AlzPredSVV.calc.txt  
  
AlzPred-SVV @ Bio-AIMS  
Alzheimer Prediction by Spectroscopy Voxel Volume  
Features: 2 volumes (Total volume of the spectroscopic voxel and Cerebrospinal fluids) in left hippocampus  
True Positive Rate = 0.812 | False Positive Rate = 0.204  
Results = http://bio-aims.udc.es/Results/21679563b3bbcbbedb/AlzPredSVV.calc.txt  
2015-11-05 12:21:33  
  
=== INPUT DATA ===  
  
Case1 3.5 2.4  
Case2 4.3 4.2  
Case3 4.5 1.0  
Case4 2.0 0.9  
  
=== Predictions on test data ===  
  
inst#    actual    predicted error prediction  
1        1:?      1:EA      0.997  
2        1:?      1:EA      1  
3        1:?      2:CONTROL 0.525  
4        1:?      1:EA      0.546
```

Figure 2. Output results from AlzPred-SVV

3. Materials and Methods

A gender-matched cohort of 260 subjects was used to test and evaluate the effectiveness of machine-learning schemes for single-subject level classification of individuals affected by different stages of dementia based on ¹H-MRS data [6]. The collection of Weka algorithms was used for this purpose. The study found that the

best classifier is a single-layer perceptron with only 2 spectroscopic voxel volumes in the left hippocampus (AUROC:0.86; True positives rate: 0.81; False positives rate:0.20). This model was implemented in AlzPred-SVV. The tool is based on an HTML/PHP user interface with a Python/Java implementation of the model.

4. Conclusions

MR modalities produce extremely high-dimensional raw data that can contain inherent patterns related to AD and machine-learning methods provide tools to observe inherent disease-related patterns in the data. This fact is presented in this work, where just the proportion of CSF within the spectroscopic voxel can discriminate AD from MCI patients and from healthy controls. AlzPred-SVV is an easy-to-use web application that can be useful for both clinicians and patients.

Acknowledgments

This work is supported by the "Collaborative Project on Medical Informatics (CIMED)" PI13/00280 funded by the Carlos III Health Institute from the Spanish National plan for Scientific and Technical Research and Innovation 2013-2016 and the European Regional Development Fund (ERDF). The authors thank the DEMCAM project team, a multicentre study with patients from different centres for dementia in the Autonomous Region of Madrid.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Li T.Q.; Wahlund L.O. The search for neuroimaging biomarkers of Alzheimer's disease with advanced MRI techniques. *Acta Radiology* **2011**, 211–222.
2. Grundman M.; et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. *Archives of Neurology* **2004** 61(1), 59-66.
3. Falahati F.; Westman E.; Simmons A. Multivariate data analysis and machine learning in alzheimer's disease with a focus on structural magnetic resonance imaging. *Journal of Alzheimer's Disease* **2014** 41(3), 685-708.
4. Frederick B.D.; et al. In vivo proton magnetic resonance spectroscopy of the temporal lobe in alzheimer's disease. *Progress in neuro-psychopharmacology & biological psychiatry* **2004**, 28(8), 1313-1322.
5. Ross A.J.; Sachdev P.S. Magnetic resonance spectroscopy in cognitive research. *Brain research. Brain research reviews*, **2004** 44(2-3), 83-102.
6. Munteanu R.C.; et al. Classification of mild cognitive impairment and Alzheimer's disease with machine-learning techniques using 1H Magnetic Resonance Spectroscopy data. *Expert Systems with Applications*. **2015** 42, 6205-6214.

7. Bio-AIMS. Artificial Intelligence Model Server in Biosciences. Available online: <http://bio-aims.udc.es> (accessed on 05 November 2015).

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions defined by MDPI AG, the publisher of the Sciforum.net platform. Sciforum papers authors the copyright to their scholarly works. Hence, by submitting a paper to this conference, you retain the copyright, but you grant MDPI AG the non-exclusive and unrevocable license right to publish this paper online on the Sciforum.net platform. This means you can easily submit your paper to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher). (<http://sciforum.net/about>).